延迟使用莱沃多巴可以预防帕金森病的运动并发症吗? 一个元分析
Luis Guilherme Ramanzini1, Julia M Frare2, Luís F M Camargo1
1Medical School, Federal University of Santa Maria (UFSM), Santa Maria, Brazil.
Movement disorders clinical practice
|August 27, 2024
概括
对帕金森病 (PD) 推迟使用莱沃多巴治疗并不能预防运动并发症. 早期的勒沃多巴启动显示了较少的运动波动,但辅助多巴胺激动剂可能会减少动力障碍,尽管有潜在的副作用.
科学领域:
- 神经学 神经学
- 临床药理学 临床药理学
背景情况:
- 关于延迟勒沃多巴开始是否会影响帕金森病 (PD) 的运动并发症的长期争论仍在继续.
- 了解利沃多巴治疗的最佳时间对于管理PD进展和患者的生活质量至关重要.
研究的目的:
- 进行随机临床试验 (RCT) 的元分析,比较早期开始与延迟开始的勒沃多巴治疗.
- 评估治疗时间对运动并发症,运动波动和运动障碍的发生的影响.
主要方法:
- 在2023年7月1日之前,对PubMed,EMBASE和Web of Science数据库进行了系统审查.
- 包括的研究是RCT,比较了PD中早期和延迟的Levodopa启动,并考虑了非随机的后续比较.
- 评估的主要结局是整体运动并发症,运动波动和运动障碍.
主要成果:
- 分析了7项涉及1149名患者的研究 (636名早期开始,513名延迟开始).
- 在早期和延迟组之间,在整体运动并发症 (OR 1.39) 或动力障碍 (OR 1.52) 中没有发现显著差异.
- 在早期开始组中,运动波动的频率较低 (OR 0.70;P=0.02).
- 亚组分析表明,当多巴胺激动剂被辅助使用时,延迟开始的功能障碍较少 (OR 1.82).
结论:
- 延迟勒沃多巴治疗似乎无法预防帕金森病的运动并发症.
- 使用多巴胺激动剂的辅助治疗可能会降低勒沃多巴的剂量需求并降低运动障碍的风险,但会带来与多巴胺激动剂相关的不良反应的风险.
相关概念视频
01:24Parkinson's Disease: Treatment
239
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
239
01:15Parkinson's Disease: Overview
500
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
500
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
281
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
281
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
104
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
104
01:29Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K